Literature DB >> 335987

Lymphocyte monitoring as a predictor of renal allograft rejection.

S B Leapman, D M Strong, S Alpert, N J Feduska, K W Sell.   

Abstract

The ability to predict acute renal allograft rejection episodes or infectious potentials by immunologic monitoring was studied in 15 renal transplant recipients. Specifically, total circulating erythrocyte- (E) and erythrocyte-antibody-complement (EAC) rosetting cells were serially studied for the first two months after transplantation and related to immunosuppressive therapy and rejection activity. Total circulating, E-rosetting cells (T cells) were noted to be significantly depressed if rabbit anti-human thymocyte globulin (RAHTG) was used in the immunosuppression protocol. The rate at which these T cells repopulated the circulation was measured by calculating their slope (delta total E-rosettes/delta time). Patients with acute rejection had an average slope of 3.2 +/- 0.68 compared to those without rejection, whose slope was 0.74 +/- 0.35 (p less than 0.01). The rapid repopulation of T cells occurred about 10 days before clinical parameters of rejection were evident. The incidence of infection was greater in those patients with total E-rosettes less than 200/mm3. Serial monitoring of total E-rosetting cells after transplantation provides a diagnostic tool for predicting ensuing rejections and can also be used to gain information concerning the susceptibility to infection.

Entities:  

Mesh:

Year:  1977        PMID: 335987      PMCID: PMC1396313          DOI: 10.1097/00000658-197711000-00004

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  25 in total

1.  T-rosettes in hemodialysis patients and renal allograft recipients.

Authors:  D P Sengar; D B Hyslop; A Rashid; J E Harris
Journal:  Cell Immunol       Date:  1975-11       Impact factor: 4.868

2.  The immunological role of different lymphoid organs in the chicken. I. Dissociation of immunological responsiveness.

Authors:  N L WARNER; A SZENBERG; F M BURNET
Journal:  Aust J Exp Biol Med Sci       Date:  1962-10

3.  The use of in vitro lymphocyte responsiveness to specific mitogenic agents in the immunological monitoring of human renal allograft recipients.

Authors:  D Copeland; A Rashid; T Stewart; J Harris
Journal:  Tissue Antigens       Date:  1974

4.  In-vitro leucocyte migration in renal transplantation.

Authors:  M K Green; G J Clunie
Journal:  Med J Aust       Date:  1974-05-11       Impact factor: 7.738

5.  Rejection crises in human renal transplant recipients: control with high dose methylprednisolone therapy.

Authors:  J G Turcotte; N J Feduska; E W Carpenter; F D McDonald; G E Bacon
Journal:  Arch Surg       Date:  1972-08

6.  Cell-mediated and humoral immune responses or renal transplant recipients with cytomegalovirus infections.

Authors:  C Lopez; R L Simmons; B H Park; J S Najarian; R A Good
Journal:  Clin Exp Immunol       Date:  1974-04       Impact factor: 4.330

7.  Letter: "Percent T. cells": an ambiguous reporting technique.

Authors:  A L Dellon
Journal:  Lancet       Date:  1974-04-20       Impact factor: 79.321

8.  Changes in human mixed lymphocyte culture reactivity as an indicator of kidney rejection.

Authors:  B G Hattler; J Miller
Journal:  Transplant Proc       Date:  1972-12       Impact factor: 1.066

9.  Effects of corticosteroids on human monocyte function.

Authors:  J J Rinehart; S P Balcerzak; A L Sagone; A F LoBuglio
Journal:  J Clin Invest       Date:  1974-12       Impact factor: 14.808

10.  Thymus-derived rosette-forming cells in various human disease states: cancer, lymphoma, bacterial and viral infections, and other diseases.

Authors:  J Wybran; H H Fudenberg
Journal:  J Clin Invest       Date:  1973-05       Impact factor: 14.808

View more
  1 in total

1.  Active T and EA-rosette-forming cells in human cadaver renal allograft recipients.

Authors:  D P Sengar; A Rashid; J E Harris
Journal:  Clin Exp Immunol       Date:  1979-02       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.